Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

(2013) David Devos et al.   ANTIOXIDANTS & REDOX SIGNALING

Neuromelanin of the Human Substantia Nigra: An Update

(2013) Fabio A. Zucca et al.   NEUROTOXICITY RESEARCH

Systemic Iron Homeostasis

(2013) Tomas Ganz   PHYSIOLOGICAL REVIEWS

Fluid and white matter suppression with the MP2RAGE sequence

(2011) Mark Tanner et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia

(2010) Daniel Velasco-Sánchez et al.   CEREBELLUM

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration

(2010) David T. Dexter et al.   JOURNAL OF NEURAL TRANSMISSION

The relevance of iron in the pathogenesis of Parkinson’s disease

(2010) Jeswinder Sian-Hülsmann et al.   JOURNAL OF NEUROCHEMISTRY

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease

(2009) Deepinder Kaur et al.   BRAIN RESEARCH

Peripheral cytokines profile in Parkinson’s disease

(2008) M. Reale et al.   BRAIN BEHAVIOR AND IMMUNITY

Increased SNR and reduced distortions by averaging multiple gradient echo signals in 3D FLASH imaging of the human brain at 3T

(2008) Gunther Helms et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism

(2008) Bogdan Brodacki et al.   NEUROSCIENCE LETTERS